Medication Study for Adolescents with Fragile X

Research has identified the protein MGLUR5 as a neurochemical target for reducing characteristic behavior problems in adults with Fragile X. This medication should block this protein from being used in the brain. The purpose of this study is to assess the safety and usefulness of three doses in treating behavioral symptoms of Fragile X. There will be 9 visits with our Fragile X expert clinicians and 9 phone calls over 20 weeks.

Visits may include at no cost to you:

- behavioral and cognitive assessments
- blood or urine samples
- physical and neurological exams
- in 1-to-3-hour visits
- compensation for time and travel

Contact Sarah at (615) 936-3288, sarah.marler@vanderbilt.edu

Date of IRB Approval: 2/14/2013

Study conducted by Jeremy Veenstra-VanderWeele, MD., Kevin Sanders, M.D. & Cassandra Newsom, Psy.D and sponsored by Novartis